Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MainStreet Bancshares Inc | Richard Alexander Vari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 20.36 per share. | 09 Jan 2026 | 10,000 | 32,882 (0%) | 0% | 20.4 | 203,600 | Common Stock |
| Lakeland Ind Inc | James Calven Swinea | Interim CFO | Purchase of securities on an exchange or from another person at price $ 8.71 per share. | 09 Jan 2026 | 1,000 | 7,305 (0%) | 0% | 8.7 | 8,710 | Common Stock, par value $.01 per share |
| Xenia Hotels & Resorts Inc | Marcel Verbaas | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 347,688 | 1,520,420 | - | - | LTIP Units | |
| Xenia Hotels & Resorts Inc | Barry A.N. Bloom | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 171,324 | 682,975 | - | - | LTIP Units | |
| Cosmos Health Inc | Grigorios Siokas | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 08 Jan 2026 | 156,190 | 7,131,794 | - | 0.5 | 81,000 | Common Stock, par value $.001 |
| Xenia Hotels & Resorts Inc | Atish Shah | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 131,012 | 203,970 | - | - | LTIP Units | |
| Xenia Hotels & Resorts Inc | Taylor C. Kessel | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 80,622 | 168,533 | - | - | LTIP Units | |
| Xenia Hotels & Resorts Inc | Joseph T. Johnson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 55,428 | 113,411 | - | - | LTIP Units | |
| UiPath Inc (Class A) | Daniel Dines | Director, CEO and Chairman, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.49 per share. | 08 Jan 2026 | 45,000 | 28,253,585 | - | 17.5 | 787,190 | Class A Commmon Stock |
| TFS Fin Corp | Anthony J. Asher | Director | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 44,314 | 44,314 (0%) | 0% | 0 | Common Stock | |
| TFS Fin Corp | Anthony J. Asher | Director | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 39,114 | 0 (0%) | 0% | 0 | Common Stock | |
| Cognex Corp | Anthony Sun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.72 per share. | 08 Jan 2026 | 26,000 | 52,608 (0%) | 0% | 16.7 | 434,720 | Common Stock |
| Cognex Corp | Anthony Sun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2026 | 26,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| AMC Entertainment Holdings Inc (Class A) | Edwin F. Gladbach | SVP, GC AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2026 | 13,269 | 23,344 (0%) | 0% | 0 | CLASS A COMMON STOCK | |
| AMC Entertainment Holdings Inc (Class A) | Edwin F. Gladbach | SVP, GC AND SECRETARY | 08 Jan 2026 | 7,126 | 14,254 | - | - | RESTRICTED STOCK UNITS | ||
| AMC Entertainment Holdings Inc (Class A) | Edwin F. Gladbach | SVP, GC AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 08 Jan 2026 | 6,799 | 16,545 (0%) | 0% | 0 | CLASS A COMMON STOCK | |
| AMC Entertainment Holdings Inc (Class A) | Edwin F. Gladbach | SVP, GC AND SECRETARY | 08 Jan 2026 | 5,263 | 5,264 | - | - | RESTRICTED STOCK UNITS | ||
| TFS Fin Corp | Anthony J. Asher | Director | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 5,200 | 0 (0%) | 0% | 0 | Common Stock | |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.34 per share. | 08 Jan 2026 | 5,000 | 66,740 (0%) | 0% | 19.3 | 96,700 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Jan 2026 | 5,000 | 61,740 (0%) | 0% | 30.0 | 150,005 | Ordinary Shares |
| Alkermes PLC | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2026 | 5,000 | 31,356 | - | - | Employee Stock Option (Right to Buy) | |
| AAR Corp | Jessica A. Garascia | Senior VP, GC, CAO & Secretary | Sale of securities on an exchange or to another person at price $ 95.25 per share. | 08 Jan 2026 | 4,787 | 29,557 (0%) | 0% | 95.3 | 455,975 | Common Stock |
| Tiptree Inc | Lesley Goldwasser | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 2,048 | 114,410 (0%) | 0% | 0 | Common Stock | |
| Tiptree Inc | Paul M. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2026 | 2,048 | 122,398 (0%) | 0% | 0 | Common Stock | |
| Peoples Bancorp Inc (Marietta, OH) | Carol A. Schneeberger | Director | Sale of securities on an exchange or to another person at price $ 30.60 per share. | 08 Jan 2026 | 1,000 | 22,204 (0%) | 0% | 30.6 | 30,600 | Common Stock |
| Home Bancshares Inc | Alex R. Lieblong | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 883 | 560,645 (0%) | 0% | 0 | Common Stock | |
| AMC Entertainment Holdings Inc (Class A) | Edwin F. Gladbach | SVP, GC AND SECRETARY | 08 Jan 2026 | 880 | 0 | - | - | RESTRICTED STOCK UNITS | ||
| Maui Land & Pineapple Co. Inc | Wade K. Kodama | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 08 Jan 2026 | 695 | 25,582 (0%) | 0% | 0 | Common Stock | |
| TotalEnergies SE (ADR) | Patrick Pouyanne | Executive Director,Chairman and Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 53.00 per share. | 08 Jan 2026 | 65 | 510,288 (0%) | 0% | 53 | 3,445 | Ords 2.50p |
| Permian Resources Corp (Class A) | William J. Quinn | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 6,914,410 | 0 | - | - | Common Units | |
| Permian Resources Corp (Class A) | William J. Quinn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 6,914,410 | 8,226,839 (2%) | 2% | - | Class A Common Stock | |
| Permian Resources Corp (Class A) | William J. Quinn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 1,018,745 | 1,018,745 (0%) | 0% | - | Class A Common Stock | |
| Permian Resources Corp (Class A) | William J. Quinn | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,018,745 | 0 | - | - | Common Units | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 560,888 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 275,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Netflix | Ted Sarandos | Director, Co-CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 207,420 | 359,100 (0%) | 0% | 0 | Common Stock | |
| Netflix | Gregory K. Peters | Director, Co-CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 207,420 | 329,560 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 135,540 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cosmos Health Inc | Grigorios Siokas | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 07 Jan 2026 | 124,880 | 6,975,604 | - | 0.5 | 65,000 | Common Stock, par value $.001 |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 115,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Netflix | Gregory K. Peters | Director, Co-CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.65 per share. | 07 Jan 2026 | 101,639 | 227,921 (0%) | 0% | 90.6 | 9,213,575 | Common Stock |
| Netflix | Ted Sarandos | Director, Co-CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.65 per share. | 07 Jan 2026 | 101,608 | 257,492 (0%) | 0% | 90.6 | 9,210,765 | Common Stock |
| Emerald Holding Inc | Herve Sedky | CEO & President | Sale or transfer of securities back to the company at price $ 4.62 per share. | 07 Jan 2026 | 96,412 | 437,427 (0%) | 0% | 4.6 | 445,423 | Common Stock |
| Proassurance Corp | Edward L. Rand | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 95,714 | 95,714 | - | - | Restricted Stock Units | |
| KLX Energy Services Holdings Inc | Keefer M. Lehner | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 94,306 | 24,895 (0%) | 0% | 0 | Common stock | |
| Emerald Holding Inc | Issa Jouaneh | President, Connections Group | Sale or transfer of securities back to the company at price $ 4.62 per share. | 07 Jan 2026 | 88,542 | 181,875 (0%) | 0% | 4.6 | 409,064 | Common Stock |
| Emerald Holding Inc | David B. Doft | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 4.62 per share. | 07 Jan 2026 | 71,621 | 154,384 (0%) | 0% | 4.6 | 330,889 | Common Stock |
| Netflix | Spencer Adam Neumann | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 70,260 | 107,170 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 67,498 | 0 (0%) | 0% | 221.5 | 14,950,807 | Common Stock |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 62,597 | 0 | - | - | Employee Stock Option (right to buy) | |
| MeiraGTx Holdings PLC | Alexandria Forbes | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 62,500 | 1,370,233 (3%) | 0% | - | Ordinary Shares | |
| MeiraGTx Holdings PLC | Alexandria Forbes | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 62,500 | 0 | - | - | Restricted Share Units | |
| MeiraGTx Holdings PLC | Richard Giroux | CFO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 52,500 | 881,994 (2%) | 0% | - | Ordinary Shares | |
| MeiraGTx Holdings PLC | Richard Giroux | CFO & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 52,500 | 0 | - | - | Restricted Share Units | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 51,999 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 50,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| UiPath Inc (Class A) | Daniel Dines | Director, CEO and Chairman, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 17.32 per share. | 07 Jan 2026 | 45,000 | 28,298,585 | - | 17.3 | 779,319 | Class A Commmon Stock |
| Netflix | David Hyman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 43,500 | 359,600 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 43,125 | 0 (0%) | 0% | - | Common Stock | |
| Intuit | Sasan K. Goodarzi | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 650.10 per share. | 07 Jan 2026 | 40,960 | 13,651 (0%) | 0% | 650.1 | 26,627,920 | Common Stock |
| MeiraGTx Holdings PLC | Stuart Naylor | CHIEF DEV. OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 37,500 | 0 | - | - | Restricted Share Units | |
| MeiraGTx Holdings PLC | Stuart Naylor | CHIEF DEV. OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 37,500 | 660,791 (1%) | 0% | - | Ordinary Shares | |
| Emerald Holding Inc | Sara Altschul | EVP and General Counsel | Sale or transfer of securities back to the company at price $ 4.62 per share. | 07 Jan 2026 | 36,155 | 70,182 (0%) | 0% | 4.6 | 167,036 | Common Stock |
| Green Plains Inc | Michelle S. Mapes | Chief Legal and Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 07 Jan 2026 | 34,906 | 33,337 (0%) | 0% | 9.8 | 342,079 | Common Stock |
| MeiraGTx Holdings PLC | Alexandria Forbes | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 07 Jan 2026 | 34,074 | 1,336,159 (3%) | 0% | 7.7 | 263,392 | Ordinary Shares |
| Green Plains Inc | Michelle S. Mapes | Chief Legal and Admin Officer | Grant, award, or other acquisition of securities at price $ 9.80 per share. | 07 Jan 2026 | 33,904 | 67,241 (0%) | 0% | 9.8 | 332,259 | Common Stock |
| Netflix | Spencer Adam Neumann | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.65 per share. | 07 Jan 2026 | 33,383 | 73,787 (0%) | 0% | 90.7 | 3,026,169 | Common Stock |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 30,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Lindblad Expeditions Holdings Inc | Benjamin Bressler | *Founder & CEO of NHA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 07 Jan 2026 | 29,628 | 53,094 (0%) | 0% | 8.4 | 250,060 | Common Stock |
| Lindblad Expeditions Holdings Inc | Benjamin Bressler | *Founder & CEO of NHA | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 07 Jan 2026 | 29,628 | 23,466 (0%) | 0% | 15.0 | 445,605 | Common Stock |
| Lindblad Expeditions Holdings Inc | Benjamin Bressler | *Founder & CEO of NHA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 29,628 | 736,600 | - | - | Stock Option (right to buy) | |
| MeiraGTx Holdings PLC | Richard Giroux | CFO & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 07 Jan 2026 | 28,822 | 853,172 (2%) | 0% | 7.7 | 222,794 | Ordinary Shares |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 27,174 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 26,249 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 25,083 | 0 (0%) | 0% | 221.5 | 5,555,885 | Common Stock |
| Proassurance Corp | Jeffrey P. Lisenby | Executive Vice-President, Secretary & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 23,720 | 23,720 | - | - | Restricted Stock Units | |
| Proassurance Corp | Kevin M. Shook | President of a Subsidiary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 23,720 | 23,720 | - | - | Restricted Stock Units | |
| Proassurance Corp | Dana S. Hendricks | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 23,720 | 23,720 | - | - | Restricted Stock Units | |
| Proassurance Corp | Robert David Francis | Pres Healthcare Pro. Liability | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 23,720 | 23,720 | - | - | Restricted Stock Units | |
| Flowco Holdings Inc (Class A) | Chad Roberts | EVP, Production Solutions | Sale of securities on an exchange or to another person at price $ 19.34 per share. | 07 Jan 2026 | 23,428 | 170,898 | - | 19.3 | 453,133 | Class A Common Stock |
| Emerald Holding Inc | Danielle Puceta | EVP, Content & Commerce | Sale or transfer of securities back to the company at price $ 4.62 per share. | 07 Jan 2026 | 22,382 | 43,446 (0%) | 0% | 4.6 | 103,405 | Common Stock |
| Cidara Therapeutics Inc | Daniel D. Burgess | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 20,500 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Theodore R. Schroeder | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 20,500 | 0 | - | - | Stock Option (right to buy) | |
| Netflix | David Hyman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.65 per share. | 07 Jan 2026 | 20,061 | 339,539 (0%) | 0% | 90.7 | 1,818,530 | Common Stock |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 20,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Allstate | Suren K. Gupta | President,Enterprise Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.32 per share. | 07 Jan 2026 | 19,593 | 120,239 (0%) | 0% | 62.3 | 1,221,036 | Common Stock |
| Allstate | Suren K. Gupta | President,Enterprise Solutions | Sale of securities on an exchange or to another person at price $ 210.00 per share. | 07 Jan 2026 | 19,593 | 100,646 (0%) | 0% | 210 | 4,114,530 | Common Stock |
| Allstate | Suren K. Gupta | President,Enterprise Solutions | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 19,593 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 19,000 | 0 | - | - | Stock Option (right to buy) | |
| Proassurance Corp | Noreen L. Dishart | Executive VP/Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 18,477 | 18,477 | - | - | Restricted Stock Units | |
| MeiraGTx Holdings PLC | Stuart Naylor | CHIEF DEV. OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 07 Jan 2026 | 17,625 | 643,166 (1%) | 0% | 7.7 | 136,241 | Ordinary Shares |
| MeiraGTx Holdings PLC | Robert K. Zeldin | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 17,500 | 154,020 (0%) | 0% | - | Ordinary Shares | |
| MeiraGTx Holdings PLC | Robert K. Zeldin | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 17,500 | 0 | - | - | Restricted Share Units | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 16,499 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 16,499 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 16,000 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 16,000 | 0 | - | - | Stock Option (right to buy) | |
| Fennec Pharma Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 07 Jan 2026 | 14,184 | 191,100 (0%) | 0% | 2.5 | 34,751 | Common shares |
| Fennec Pharma Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 14,184 | 836,567 | - | - | Stock Options | |
| Gaming and Leisure Properties Inc | Steven L. Ladany | SVP Chief Development Officer | Sale of securities on an exchange or to another person at price $ 45.04 per share. | 07 Jan 2026 | 13,409 | 57,886 (0%) | 0% | 45.0 | 603,941 | Common Stock |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 13,249 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 12,553 | 8,333 (0%) | 0% | 221.5 | 2,780,490 | Common Stock |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 12,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 12,499 | 0 | - | - | Employee Stock Option (right to buy) | |
| Tilray Brands Inc | Steven M. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.99 per share. | 07 Jan 2026 | 12,438 | 12,438 | - | 9.0 | 111,818 | Common Stock |
| Tilray Brands Inc | Steven M. Cohen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 12,438 | 0 | - | - | Restricted Stock Units | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,749 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Daniel D. Burgess | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Theodore R. Schroeder | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Ryan Spencer | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | James Merson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,100 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 11,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Figs Inc (Class A) | Sarah Oughtred | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 07 Jan 2026 | 10,515 | 834,830 | - | 11.5 | 120,927 | Class A Common Stock |
| KLX Energy Services Holdings Inc | Keefer M. Lehner | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 10,148 | 0 | - | - | Restricted Stock Unit | |
| Calix Inc | Carl Russo | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.63 per share. | 07 Jan 2026 | 10,000 | 3,983,070 (7%) | 0% | 12.6 | 126,300 | Common Stock |
| Calix Inc | Carl Russo | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 10,000 | 570,000 | - | - | Stock Option (right to buy) | |
| Alphabet (Class A) | Sundar Pichai | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 322.11 per share. | 07 Jan 2026 | 9,280 | 2,249,131 (0%) | 0% | 322.1 | 2,989,181 | Class C Capital Stock |
| Alphabet (Class A) | Sundar Pichai | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 320.10 per share. | 07 Jan 2026 | 9,079 | 2,264,693 (0%) | 0% | 320.1 | 2,906,188 | Class C Capital Stock |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 8,333 | 0 (0%) | 0% | - | Common Stock | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 7,949 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 7,526 | 43,125 (0%) | 0% | 221.5 | 1,667,009 | Common Stock |
| MeiraGTx Holdings PLC | Robert J. Wollin | GENERAL COUNSEL AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 7,500 | 33,646 (0%) | 0% | - | Ordinary Shares | |
| MeiraGTx Holdings PLC | Robert J. Wollin | GENERAL COUNSEL AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 7,500 | 0 | - | - | Restricted Share Units | |
| NRG Energy | Woo-Sung Bruce Chung | EVP & CFO | Sale of securities on an exchange or to another person at price $ 158.79 per share. | 07 Jan 2026 | 7,383 | 79,147 (0%) | 0% | 158.8 | 1,172,374 | Common Stock, par value $.01 per share |
| Everspin Tech Inc | William Cooper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 07 Jan 2026 | 6,807 | 93,193 (0%) | 0% | 12.1 | 82,092 | Common Stock |
| MeiraGTx Holdings PLC | Robert K. Zeldin | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 07 Jan 2026 | 6,729 | 147,291 (0%) | 0% | 7.7 | 52,015 | Ordinary Shares |
| Alphabet (Class A) | Sundar Pichai | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 321.21 per share. | 07 Jan 2026 | 6,282 | 2,258,411 (0%) | 0% | 321.2 | 2,017,841 | Class C Capital Stock |
| Cidara Therapeutics Inc | Shane M. Ward | COO & CLO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 6,207 | 0 | - | - | Employee Stock Option (right to buy) | |
| Arteris Inc | Nicholas B. Hawkins | VP and Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.27 per share. | 07 Jan 2026 | 5,836 | 82,267 | - | 17.3 | 100,799 | Common Stock |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 5,763 | 0 (0%) | 0% | 221.5 | 1,276,505 | Common Stock |
| EverQuote Inc (Class A) | David Brainard | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 07 Jan 2026 | 5,709 | 101,603 (0%) | 0% | 25.0 | 143,010 | Class A Common Stock |
| Cidara Therapeutics Inc | Nicole Negar Davarpanah | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 5,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| NRG Energy | Woo-Sung Bruce Chung | EVP & CFO | Sale of securities on an exchange or to another person at price $ 153.25 per share. | 07 Jan 2026 | 5,000 | 86,530 (0%) | 0% | 153.3 | 766,258 | Common Stock, par value $.01 per share |
| EverCommerce Inc | Matthew David Feiersrtein | President | Sale of securities on an exchange or to another person at price $ 12.10 per share. | 07 Jan 2026 | 5,000 | 2,065,919 | - | 12.1 | 60,510 | Common Stock |
| ResMed | Michael J. Farrell | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 07 Jan 2026 | 4,991 | 471,214 (0%) | 0% | 146.3 | 730,383 | ResMed Common Stock |
| ResMed | Michael J. Farrell | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 248.46 per share. | 07 Jan 2026 | 4,991 | 466,223 (0%) | 0% | 248.5 | 1,240,065 | ResMed Common Stock |
| ResMed | Michael J. Farrell | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 4,991 | 49,912 | - | - | ResMed Common Stock Options | |
| Codexis Inc | Stefan Lutz | CSO | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 07 Jan 2026 | 4,685 | 138,775 (0%) | 0% | 1.7 | 7,950 | Common Stock |
| MeiraGTx Holdings PLC | Robert J. Wollin | GENERAL COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 07 Jan 2026 | 4,364 | 29,282 (0%) | 0% | 7.7 | 33,734 | Ordinary Shares |
| Cidara Therapeutics Inc | Ryan Spencer | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 4,250 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | James Merson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 4,250 | 0 | - | - | Stock Option (right to buy) | |
| Invesco Quality Municipal Income Trust | Jack Connelly | Portfolio Manager | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 07 Jan 2026 | 3,900 | 5,500 (0%) | 0% | 10.0 | 39,078 | Common Shares |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 3,320 | 0 (0%) | 0% | 221.5 | 735,380 | Common Stock |
| Alphabet (Class A) | Sundar Pichai | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 323.05 per share. | 07 Jan 2026 | 2,750 | 2,246,381 (0%) | 0% | 323.1 | 888,388 | Class C Capital Stock |
| FactSet Research | Robin A. Abrams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 207.88 per share. | 07 Jan 2026 | 2,572 | 14,886 (0%) | 0% | 207.9 | 534,667 | Common Stock |
| FactSet Research | Robin A. Abrams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 2,572 | 0 | - | - | Non-Employee Director Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Jeffrey Stein | Director, President & CEO | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 2,379 | 0 (0%) | 0% | 221.5 | 526,949 | Common Stock |
| Kewaunee Scientific Corp | Thomas D. Hull | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 37.50 per share. | 07 Jan 2026 | 2,177 | 33,000 (1%) | 0% | 37.5 | 81,638 | Common Stock |
| Hurco Companies Inc | Michael Doar | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.30 per share. | 07 Jan 2026 | 2,147 | 217,182 (3%) | 0% | 16.3 | 34,996 | Common Stock |
| Cidara Therapeutics Inc | Daniel D. Burgess | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Daniel D. Burgess | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Theodore R. Schroeder | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Theodore R. Schroeder | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Ryan Spencer | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | James Merson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 2,125 | 0 | - | - | Stock Option (right to buy) | |
| Clover Health Investments Corp (Class A) | Jamie L. Reynoso | CEO, Medicare Advantage | Sale of securities on an exchange or to another person at price $ 2.53 per share. | 07 Jan 2026 | 2,102 | 2,757,029 | - | 2.5 | 5,318 | Class A Common Stock |
| PACCAR | Mark C. Pigott | Director, Executive Chairman | Other type of transaction at price $ 115.31 per share. | 07 Jan 2026 | 2,074 | 174,646 (0%) | 0% | 115.3 | 239,160 | Common Stock |
| Axon | Patrick W. Smith | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 619.90 per share. | 07 Jan 2026 | 2,040 | 3,104,855 (5%) | 0% | 619.9 | 1,264,599 | Common Stock |
| Virco Manufacturing Corp | Bradley C. Richardson | Director | Purchase of securities on an exchange or from another person at price $ 6.50 per share. | 07 Jan 2026 | 2,000 | 37,754 (0%) | 0% | 6.5 | 13,009 | Common Stock $.01 par value |
| ResMed | Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 248.83 per share. | 07 Jan 2026 | 2,000 | 66,773 (0%) | 0% | 248.8 | 497,660 | ResMed Common Stock |
| Grid Dynamics Holdings Inc (Class A) | Anil Kumar Doradla | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 07 Jan 2026 | 2,000 | 376,475 | - | 10 | 20,000 | Common Stock |
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | 07 Jan 2026 | 2,000 | 508,459 | - | 0 | Class A Common Stock | ||
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 2,000 | 46,450 | - | - | Stock Option (Right to Buy) | |
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 2,000 | 2,000 | - | - | Class B Common Stock | |
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | 07 Jan 2026 | 2,000 | 0 | - | - | Class B Common Stock | ||
| Vicor Corp | Philip Davies | Director, VP Global Sales & Marketing | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.61 per share. | 07 Jan 2026 | 1,920 | 1,920 (0%) | 0% | 41.6 | 79,891 | Common Stock |
| Vicor Corp | Philip Davies | Director, VP Global Sales & Marketing | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 1,920 | 17,278 | - | - | Non Qualified Stock Option | |
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.49 per share. | 07 Jan 2026 | 1,900 | 506,559 | - | 75.5 | 143,431 | Class A Common Stock |
| Outset Medical Inc | Leslie L. Trigg | Director, Chair and CEO | Sale of securities on an exchange or to another person at price $ 4.27 per share. | 07 Jan 2026 | 1,795 | 119,617 | - | 4.3 | 7,665 | Common Stock |
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 160.09 per share. | 07 Jan 2026 | 1,754 | 436,905 (0%) | 0% | 160.1 | 280,792 | Class A Common Stock |
| Atlassian Corp (Class A) | Scott Farquhar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 160.09 per share. | 07 Jan 2026 | 1,753 | 437,955 (0%) | 0% | 160.1 | 280,632 | Class A Common Stock |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,750 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,750 | 0 | - | - | Stock Option (right to buy) | |
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 162.95 per share. | 07 Jan 2026 | 1,747 | 441,373 (0%) | 0% | 163.0 | 284,675 | Class A Common Stock |
| Atlassian Corp (Class A) | Scott Farquhar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 162.95 per share. | 07 Jan 2026 | 1,747 | 442,423 (0%) | 0% | 163.0 | 284,676 | Class A Common Stock |
| Alphabet (Class A) | Sundar Pichai | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 319.36 per share. | 07 Jan 2026 | 1,600 | 2,273,772 (0%) | 0% | 319.4 | 510,976 | Class C Capital Stock |
| Regeneron Pharma | Bonnie L. Bassler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 07 Jan 2026 | 1,500 | 3,203 (0%) | 0% | 374.1 | 561,180 | Common Stock |
| Regeneron Pharma | Bonnie L. Bassler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 1,500 | 2,861 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Bonnie L. Bassler | Director | Sale of securities on an exchange or to another person at price $ 800.00 per share. | 07 Jan 2026 | 1,500 | 1,703 (0%) | 0% | 800 | 1,200,000 | Common Stock |
| Rubrik Inc (Class A) | Kiran Choudary | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 77.02 per share. | 07 Jan 2026 | 1,500 | 505,059 | - | 77.0 | 115,530 | Class A Common Stock |
| Atlassian Corp (Class A) | Scott Farquhar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 162.23 per share. | 07 Jan 2026 | 1,471 | 440,952 (0%) | 0% | 162.2 | 238,638 | Class A Common Stock |
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 162.23 per share. | 07 Jan 2026 | 1,470 | 439,903 (0%) | 0% | 162.2 | 238,476 | Class A Common Stock |
| Axon | Patrick W. Smith | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 619.00 per share. | 07 Jan 2026 | 1,469 | 3,106,895 (5%) | 0% | 619.0 | 909,314 | Common Stock |
| Axon | Patrick W. Smith | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 621.07 per share. | 07 Jan 2026 | 1,427 | 3,103,428 (5%) | 0% | 621.1 | 886,263 | Common Stock |
| Cidara Therapeutics Inc | Daniel D. Burgess | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,400 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Theodore R. Schroeder | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,400 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Chrysa Mineo | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,400 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Bonnie L. Bassler | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,400 | 0 | - | - | Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Carin Canale-Theakston | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 1,400 | 0 | - | - | Stock Option (right to buy) | |
| SEMrush Holdings Inc (Class A) | Dmitry Melnikov | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 11.90 per share. | 07 Jan 2026 | 1,399 | 1,879,812 | - | 11.9 | 16,648 | Class A Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.